Navigation Links
Enigma Diagnostics Announces Patent Licence With Applied Biosystems

PORTON DOWN, England, Oct 22 /PRNewswire/ -- Enigma Diagnostics Limited, the decentralised and point-of-care molecular diagnostics company, announced today that it has signed a third licence agreement with Applied Biosystems.

The licence provides Enigma with access to claims of US Patent No. 5,928,907 that describe methods for monitoring nucleic acid amplification in real-time. This is the first such licence Applied Biosystems has granted to the method claims of the '907 patent.

This complements Enigma's existing licence under certain patents owned by Applied Biosystems for real-time PCR thermal cyclers.

Financial terms were not disclosed.


UK Contact:

Enigma Diagnostics

Deborah Cordingley

+44 1980 590131

US Contact:

Richard Lewis Communications, Inc.


Gregory Tiberend - Media

Megan Dubrowski - Media

Cecelia Heer - Investors

Notes to editors:

About Enigma Diagnostics Limited

Enigma Diagnostics Limited is a private UK based company specialising in developing the next generation of rapid molecular diagnostic instrument platforms for decentralised and point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for field-based, decentralised and point-of-care tests providing results from a raw sample in less than 45 minutes.

The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high value Applied Markets. Enigma's commercialisation strategy is to maximise revenues from a continuous flow of market leading rapid diagnostic point-of care and in-field instrument and assay platforms, derived from its broad Intellectual Property portfolio of issued and filed patents. Enigma will partner with market leaders where global penetration of markets is required and where appropriate will build an in-house sales and marketing capability to direct distribution of its products.

Enigma has an exclusive licence from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded research and has licences from Applied Biosystems and Celera Licences for the commercialisation of real-time PCR instruments. Enigma's R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.

For more information visit

SOURCE Enigma Diagnostics Limited
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Enigma Diagnostics Announces an Award of GBP 1.8 Million From UK Government
2. Enigma Signs Real-Time PCR Licences With Applera
3. Enigma Diagnostics to Develop Clinical Diagnostics Platform for UK National Chlamydia Screening Programme
4. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
5. Golub Capital Provides Debt Financing to Support the Acquisition of DNA Diagnostics Center, Inc. by MTS Health Investors, LLC
6. Exiqon A/S Announces U.S. Subsidiary Name Change From Oncotech, Inc. to Exiqon Diagnostics, Inc.
7. Axial Biotech Appoints Retired Roche Diagnostics Executive to Board
8. Pathwork Diagnostics Announces Key Additions to Management Team
9. InformationWeek Puts Roche Diagnostics on Top 500 Innovative Tech Users List
10. Fujirebio Diagnostics Named One of the Best Places to Work in Pennsylvania
11. Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics
Post Your Comments:
(Date:6/27/2016)... ... June 27, 2016 , ... Cancer experts from Austria, Hungary, ... be a new and helpful biomarker for malignant pleural mesothelioma. Surviving Mesothelioma has ... it now. , Biomarkers are components in the blood, tissue or body ...
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
Breaking Biology Technology:
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
Breaking Biology News(10 mins):